Two of Canada's best-known cannabis names plan to combine. Organigram Global has signed a deal to buy Aurora Cannabis that values Aurora at about C$561 million, The Canadian Press reports via BNN Bloomberg.
Aurora shareholders can take C$7.80 per share in cash, 5.8626 Organigram shares per Aurora share, or a mix of the two. Total cash is capped at about C$253.6 million. Both boards unanimously support the deal. The companies say it's a 21% premium over the implied value of Curaleaf's amended Oct. 6 offer. They expect it to close in January 2027, pending shareholder, regulatory and court approvals.
The deal follows a fight with U.S. operator Curaleaf, which took a hostile offer straight to Aurora shareholders in August and raised it in October. On Tuesday evening, Curaleaf said its enhanced bid "remains outstanding" and argued it offers better value.
The companies say the merger would combine Aurora's global medical cannabis platform, manufacturing and patient network with Organigram's Canadian recreational brands and European footprint, with more than C$50 million in expected synergies.
What it means for travelers: Nothing changes on the shelf yet. If you shop legally in Canada or buy medical cannabis abroad, you may eventually see familiar brands under one corporate roof. Remember that you can't carry cannabis across the U.S.–Canada border.






